INOVIO to Present at Upcoming Scientific Conferences


PLYMOUTH MEETING, Pa., Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences:

(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)

AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy
Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO
Abstract Title: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways
Date and Time: October 19, 2024, 6:00 - 8:15pm ET
Location: Boston, MA

ISV Congress 2024
Oral presentation and poster by Dr. Michael Sumner, Chief Medical Officer at INOVIO
Abstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP)
Date and Time: October 22, 2024, 4:20pm KST
Location: Seoul, Korea

Fall Voice
Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIO
Abstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP)
Date and Time: October 25October 26, 2024
Location: Phoenix, AZ

World Vaccine Congress Europe
Presentation and panel discussion by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIO
Track: Pre-Congress Workshop on Platform Technologies
Date and Time: October 28, 2024, 10:00am CET
Location: Barcelona, Spain

Abstracts from these conferences will be made available on INOVIO's website following each presentation.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conferences-302263723.html

SOURCE INOVIO Pharmaceuticals, Inc.

Werbung

Inovio Pharmaceuticals Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Inovio Pharmaceuticals nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
15.02.18 Inovio Pharmaceuticals Buy Maxim Group
18.10.17 Inovio Pharmaceuticals Outperform RBC Capital Markets
24.05.17 Inovio Pharmaceuticals Buy Maxim Group
16.03.17 Inovio Pharmaceuticals Buy Maxim Group
07.11.16 Inovio Pharmaceuticals Buy Aegis Capital

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.